Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane

2 Mar 2016

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Treatment and Pharmacology
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 27041672
DOI: 10.1016/j.ejso.2016.02.246

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxanePMID 27041672Read ↗

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.Semantic proximity Read ↗

Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancersSemantic proximity Read ↗

Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Semantic proximity Read ↗

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapySemantic proximity Read ↗

Systemic therapy options in BRCA mutation-associated breast cancer.Semantic proximity Read ↗

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.Semantic proximity Read ↗

Sensitivity of BRCA-1-related breast cancer to neoadjuvant chemotherapy: practical implications.Semantic proximity Read ↗

BRCAness revisited.Semantic proximity Read ↗

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.Semantic proximity Read ↗

Tailored therapies for triple-negative breast cancer: current landscape and future perceptionsSemantic proximity Read ↗

Association of BRCA Mutations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell LinesSemantic proximity Read ↗

Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.